GlassScriptPhysician profile
Tanya R Darrow
NPI 1831368695
$4,407.50
in general payments reported to CMS, 2019-2025
40 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $774 · 2023: $1,260 · 2024: $1,190 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,123.27 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $761.91 | 2021-2025 | |
| Lilly USA, LLC | $439.04 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $401.84 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $205.06 | 2021-2024 | |
| Glaxosmithkline, LLC. | $177.78 | 2021-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Otsuka America Pharmaceutical, INC. | $146.40 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $116.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $107.87 | 2021-2024 | Farxiga, Airsupra |
| Abbott Laboratories | $71.67 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $66.25 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $47.41 | 2022-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.15 | 2024 | |
| Merck Sharp & Dohme LLC | $45.02 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi Pasteur INC. | $44.56 | 2024-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Darrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.